

JOHAN ASKLING PUBLICATIONS 2016**Peer reviewed articles**

1. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. *European Respiratory Journal* 2016; 48: 1690-1699.
2. Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho ML, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SMM, Yamanaka H, Wesby-van Swaay E, Symmons D. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. *Annals of the Rheumatic Diseases* 2016; 75: 1789-1796.
3. Eriksson K, Nise L, Kats A, Luttrupp E, Catrina AI, Askling J, Jansson L, Alfredsson L, Klareskog L, Lundberg K, Yucel-Lindberg T. Prevalence of Periodontitis in Patients with Established Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. *Plos One* 2016; 11.
4. Exarchou S, Lie E, Lindstrom U, Askling J, Forsblad-d'Elia H, Turesson C, Kristensen LE, Jacobsson LTH. Mortality in ankylosing spondylitis: results from a nationwide population-based study. *Annals of the Rheumatic Diseases* 2016; 75: 1466-1472.
5. Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22: 85-93.
6. Frisell T, Hellgren K, Alfredsson L, Raychaudhuri S, Klareskog L, Askling J. Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. *Annals of the Rheumatic Diseases* 2016; 75: 183-189.
7. Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? *Annals of the Rheumatic Diseases* 2016; 75: 1120-1125.
8. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. *Nature Reviews Rheumatology* 2016; 12: 335-343.
9. Holmqvist M, Ljung L, Askling J. Has the improved management of newly diagnosed rheumatoid arthritis (RA) lowered the excess risk of acute coronary syndrome (ACS)? *Scandinavian Journal of Rheumatology* 2016; 45: 1-1.
10. Jakobsson GL, Stephansson O, Askling J, Jacobsson LTH. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. *Annals of the Rheumatic Diseases* 2016; 75: 1838-1842.
11. Jiang X, Askling J, Saevarsdottir S, Padyukov L, Alfredsson L, Viatte S, Frisell T. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1

- haplotypes, and response to TNFi therapy - results from a Swedish cohort study. *Arthritis Research & Therapy* 2016; 18.
12. Khalili H, Neovius M, Ekblom A, Ludvigsson JF, Askling J, Chan AT, Olen O. Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. *American Journal of Gastroenterology* 2016; 111: 1614-1620.
 13. Lindstrom U, Exarchou S, Lie E, Dehlin M, Forsblad-d'Elia H, Askling J, Jacobsson L. Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. *Arthritis Research & Therapy* 2016; 18.
 14. Lindstrom U, Forsblad-d'Elia H, Askling J, Kristensen LE, Lie E, Exarchou S, Jacobsson L. Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case-control study based on national registers. *Arthritis Research & Therapy* 2016; 18.
 15. Ljung L, Rantapaa-Dahlqvist S, Jacobsson LTH, Askling J, Artis Study G. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2016; 75: 2087-2094.
 16. Michaud K, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho ML, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Yamanaka H, Askling J. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. *Annals of the Rheumatic Diseases* 2016; 75: 1797-1805.
 17. Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. *Arthritis Research & Therapy* 2016; 18.
 18. Olofsson T, Johansson K, Eriksson JK, van Vollenhoven R, Miller H, Petersson IF, Askling J, Neovius M. Does disease activity at start of biologic therapy influence work-loss in RA patients? *Rheumatology* 2016; 55: 729-734.
 19. Raaschou P, Simard JF, Hagelberg CA, Askling J, Grp AS. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. *Bmj-British Medical Journal* 2016; 352.
 20. Saevarsdottir S, Klareskog L, Hansson M, Eriksson J, Johannesson M, Holmdahl R, Skriner K, Serre G, Mathsson-Alm L, van Vollenhoven RF, van der Woude D, Allaart R, Alfredsson L, McInnes I, Ronnelid J, Askling J. Do specific ACPAs or other autoantibodies in a novel assay predict response to methotrexate monotherapy in patients with early and DMARD-naive RA? *Scandinavian Journal of Rheumatology* 2016; 45: 19-19.
 21. Simard JF, Ekberg S, Johansson ALV, Askling J. What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer? *Annals of the Rheumatic Diseases* 2016; 75: 862-866.

22. Wadstrom H, Frisell T, Soren P, Askling J, Grp AS. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. *Annals of the Rheumatic Diseases* 2016; 75: 1272-1278.